Background The Cancer Drugs Fund (CDF) was established in 2010 to improve access to treatments not routinely available. Having widely overspent, stricter budgeting rules were introduced in 2016. The CDF can now only include treatments with potential to be cost effective once sufficient data are collected. Objectives Our objective was to explore the process and criteria used for consideration of treatments under the new CDF framework and to describe the extent of evidence collection. Methods We identified CDF list, UK National Institute for Health and Care Excellence (NICE) and Scottish Medicines Consortium documents (10 May 2018). Data were collected on drugs and indications, reasons for inclusion in the CDF, data collection, incremental cost-effectiveness ratios (ICERs), and corresponding recommendations for Scotland. Results In total, 12 drugs were listed on the CDF in 17 indications, 12 of which were considered end-of-life care. The most common cancers were non-small-cell lung (n = 4), urothelial (n = 3), lymphocytic leukaemia (n = 2) and multiple myeloma (n = 2). The companies' ICERs were generally lower than those from the committee and the evidence review group. Drugs were included in the CDF for 6-42 months, with the majority included for ≥18 months. Data were frequently collected on overall survival (n = 16) and progression-free survival (n = 5) using NHS systems and, frequently, ongoing trials. Conclusions Data collection frequently included overall survival and exceeded the 2 years recommended in the CDF strategy. It appears the CDF is allowing patients access to drugs long before they may become available for routine use. Our results are limited by the availability of published information and the small dataset. 
Introduction
Most recent data indicate that, in 2018, approximately 447,000 new cases of cancer were expected to be diagnosed in the UK [1] . This is an approximately 41% increase since the early 1990s, largely because of the ageing population [2] but also better diagnostics and broader screening programmes [3] . One of the major challenges in the UK for a number of years has been poor cancer survival compared with other high-income countries, partially attributed to limited access to treatment [4] .
Numerous new drugs have been developed in recent years to improve cancer care. These treatments may offer substantial benefit to patients over older therapies. However, these new treatments are often too expensive to be affordable for healthcare systems and individual patients. In addition, the benefit of these treatments has sometimes been questioned, with lack of data on overall survival and quality of life being an important issue, limiting their availability in national healthcare systems [5] [6] [7] [8] [9] . Another major challenge in the implementation of new cancer drugs is that treatments developed for very small patient populations may fall outside of the scope of national health technology assessment bodies, resulting in a limited number of treatment options for patients with rare disease types [10] .
To deal with these challenges, in 2010, The Cancer Drugs Fund (CDF) was set up to improve access to new cancer treatments that were not recommended by the UK National Institute for Health and Care Excellence (NICE) for routine use in the National Health Service (NHS) [11, 12] . This included both drugs that were not considered cost effective and those that have never been evaluated by NICE. Within this scope, one of the main objectives was providing additional funding for treatment of rarer forms of cancer. The CDF was set up by the UK government as a temporary solution, acting as a bridge to a newly proposed value-based pricing system that was due in 2014. As the original plans for value-based pricing were not pursued, the CDF in its original form was extended to 2016 [13] . Inclusion in the CDF was based on clinical recommendations and was limited to patients who had already exhausted all other treatments options for their type and stage of cancer [14] .
Although the CDF was aiming to increase the availability of treatments for rare disease types, a large part of its budget was in fact allocated to treatment of more common cancers. For example, in the 2 years between April 2013 and March 2015, a total of 59% of patients benefitting from the CDF were treated for the most common types of cancer, such as breast and colorectal. When the CDF was set up, the importance of collecting data on the benefit of the treatments included in the CDF was recognised. However, as this was not a formal requirement until 2014, the evidence collected was limited and gaps in the data persisted, even after 2014 [10] .
The CDF was associated with substantial costs that quickly increased throughout its lifetime: the initial annual budget of £50 million in 2010/11 was increased annually to reach £200 million in 2014 and £280 million in 2014/15. By that time, the total cost of the CDF amounted to £968 million, including an overspent £38 million. Afterwards, the CDF budget was further increased in 2015/16, resulting in a total spending of £1.27 billion throughout the existence of the CDF under the original framework [15] .
Since then, a new mechanism has been introduced to prevent the CDF from overspending. Under the new system, in cases of an overspend, a proportional rebate is applied to all companies receiving funding from the CDF budget [13] . Apart from placing a limit on CDF spending, this also suggests an indirect mechanism for further drug price reduction in case of an overspend.
Although the need to improve the availability of cancer treatments was still considered important, the continually increasing budget and doubts about the benefit delivered by the CDF suggested it cannot continue in its original format [10] . Therefore, a new framework came into effect on 1 April 2016 where treatments could only be included in the CDF to collect data necessary to address uncertainty around the clinical benefit of the drug. This was only to be undertaken for treatments evaluated by NICE and that showed potential to fall under the cost-effectiveness threshold once uncertainty had been addressed. The duration for which drugs were available on the CDF was to be as short as possible and normally not exceed 2 years. However, the exact duration for which drugs are included in the CDF would be considered on a case-by-case basis [13] . Importantly, management and financial responsibility for the new CDF was given to NHS England and required close partnership with NICE as well as other government bodies, including Public Health England (PHE). Thus, the CDF in its current format serves both as an early access scheme for drugs likely to obtain routine NHS funding and as a means of data collection to support future NICE technology appraisals [13] .
The aim of this research was to explore the process and criteria used for consideration of treatments under the new CDF framework and to describe the extent of evidence collection while in the CDF.
Methods
The CDF list was downloaded from the NHS England website [16] on 10 May 2018. To identify drugs included in the 'new CDF', drugs marked 'yes' or 'not currently applicable' to being on the CDF managed access scheme were searched on the NICE website [17] . Where available, the following documents were downloaded for the relevant indication: managed access agreement (MAA), final appraisal documentation (FAD) and committee papers including patient access schemes (PAS) and evidence review group (ERG) reports.
The Scottish Medicines Consortium (SMC) website [18] was also searched, and documents regarding the SMC's decision on whether the drug was accepted for use within NHS Scotland were downloaded where available.
A data extraction template was designed to collect data from available documents on the following:
• route to CDF entry (company submission, ERG identification or committee identification) • drug indication • clinical uncertainty leading to inclusion in the CDF • ways of data collection on the CDF, • duration of MAA • outcomes on which data were to be collected • preferred company, ERG and committee incremental cost-effectiveness ratios (ICERs) • whether the drug met NICE's end-of-life criteria • SMC recommendation on the use of the drug within NHS Scotland.
All documents used for data collection are reported in the Electronic Supplementary Material (ESM) 1.
Where data collection under the CDF included an ongoing trial, the planned completion date of the trial was obtained from the US National Library of Medicine's Clinical Trials website [19] and compared with the duration of the MAA.
Where possible, data were summarised using descriptive statistics. For ICER values, where these were reported as ranges, the midpoint of the range was used in all calculations. In cases where only the minimal plausible value was provided, this value was used to calculate the median.
Results
In total, 45 drug indications were included in the CDF list; 16 of these were marked 'yes' (available on the scheme), eight were marked 'no' (not available on the scheme), 20 were marked 'not currently applicable' and one was marked 'not applicable' (N/A). Of these, MAA, FAD and committee paper documents, including PAS and ERG reports, were identified for 17 cases (16 marked 'yes' and one as 'not currently applicable' 1 ) involving 12 drugs, which formed the basis of the present analysis. All 12 identified drugs were indicated in adults, in ten different types of cancer, as displayed in Table 1 . The most common cancers were non-small cell lung (n = 4), urothelial (n = 3), lymphocytic leukaemia (n = 2) and multiple myeloma (n = 2). According to NICE, end-of-life criteria were met in 12 cases and not met in four; in one case, the committee concluded it could not make an informed decision.
Drugs entered the CDF via two routes: inclusion in the CDF was proposed in the company submission in ten cases and by the committee in three. In four cases, the route to CDF entry was unclear. No indications were recommended by the ERG. Figure 1 shows the duration for which drugs were included in the CDF. The majority of drugs entered the CDF for ≥ 18 months. The most frequent durations of MAAs were from 18 to 24 months and from 36 to 42 months (five cases each). The median duration of an MAA was 25 months.
Six different methods of data collection were identified, as shown in Fig. 2 . In all cases, NHS data-collection systems, including Blueteq and the Systemic Anti-Cancer Therapy (SACT) dataset were used. In 15 of the 17 indications, clinical trials were used. In some of the 15 cases, additional data-collection methods were used: PHE data, not including SACT, the Early Access Programme, Clinical Patient Data Registry, and other (unspecified) real-world data.
Where data were collected as part of a clinical trial, the duration of the MAA was often explicitly selected to coincide with the completion of trials or availability of sufficiently mature data (n = 7). In the remaining cases, the drug was expected to exit the CDF while the trial was ongoing but after completion of primary data collection (n = 4) or after the completion of the trial (n = 4). In two of the 15 cases where clinical trial data were not collected [20] , the trials were already completed when the drug entered the CDF and the MAA was designed to allow a retrospective analysis or validation of data collected in clinical trials using PHE data.
Data were collected on five outcome categories, as shown in Fig. 3 . Overall survival was the most commonly assessed (16 of 17 cases) and included, for example, overall survival for the drug included in the CDF, a comparator or both, long-term overall survival and pre-progression mortality. Progression-free survival was to be collected in five cases, which included progression-free survival for the drug included in the CDF, a comparator or both. Health-related quality-of-life (HRQoL) data were collected in three cases and safety data in one. Tumour response, which included best overall response, duration of response and durable response rate, was collected in one case.
Preferred or base-case ICERs were available from both the company and the committee in 15 indications. The ERG provided ICERs for nine indications as displayed in Fig. 4a . The company's median base-case ICER per quality-adjusted life-year (QALY) gained was £43,227 (range 15,772-58,315); the committee's median preferred ICER per QALY gained was £54,386 (range 31,691 to > 100,000); the ERG's preferred median ICER per QALY gained was £60,000 (range 44,504-106,457). Figure 4b compares the company, committee and ERG's preferred ICERs for each individual drug and indication. In cases where both the company and committee provided ICERs (n = 14), 11 reported the committee's preferred ICER to be greater than the company's, two cases agreed the same ICER value and, in one case, the company's base-case ICER was greater than the committee's. The median difference between ICERs provided by both the company and the committee was £11,602. In all indications that the ERG provided ICERs, the ERG's preferred ICER was greater than the company's. In one case (obinutuzumab with bendamustine), no ICER values were available for the company, committee or the ERG.
Apart from the need to collect more outcome data, deficits in study design and lack of information on generalisability to the UK practice formed a large part of clinical uncertainty. Issues relating to study design included small numbers of patients, short clinical follow-up time, lack of comparative evidence and insufficient subgroup data. Issues relating to generalisability for use within UK practice included patient characteristics (i.e. whether the study evidence included patients with similar baseline characteristics to the intended population), duration of treatment, and treatment patterns such as patient eligibility for subsequent lines of therapy and availability of further treatment. Issues related to uncertainty surrounding study design and the generalisability for use within UK practice often overlapped with uncertainty surrounding outcomes. Some examples included lack of evidence on overall survival when compared with the standard [20, 26, 38, 45] of care [21] , lack of evidence around pre-progression mortality in the English clinical setting [22] or immature evidence on overall survival [23] .
The sources of uncertainty and data-collection items were grouped into three categories: outcomes, trial design limitations, generalisability to the UK (details provided in ESM 2). Figure 5 details how the data collected for each drug indication correspond to the reasons for inclusion of the drug in the CDF (sources of uncertainty). In all cases, there was some discrepancy between the sources of uncertainty and the data that were collected on the CDF. Most frequently, data collection was more extensive than the sources of uncertainty A Summary of ICER levels from the three stakeholders: data was available for 15 indications for the company reported in the NICE documents; in one case, this was true for all data categories considered. However, in four cases [24] [25] [26] [27] , uncertainty around study design (follow-up time and sample size) was not reported to be collected (data shown in ESM 3). Of the 17 drugs and indications on the CDF, 13 were accepted for use within the Scottish NHS. Of these, eight were accepted for restricted use and five were recommended for use without restriction. The SMCs restrictions fell in line with either the committee's recommendations or the CDF patient eligibility criteria (data shown in ESM 4). In essence, the 13 drugs were available to the same patient population in Scotland and under the CDF in England. In the remaining four drug indications, one indication was not recommended for use by the SMC because of the lack of clinical benefit in relation to the cost of the treatment; one indication was under review and awaiting a recommendation and two indications were not present on the SMC website.
Discussion
Since the proposals for the new CDF framework in 2016, its policy implications have been debated and evaluated in detail [28, 29] . Our review investigated the criteria for inclusion as well as the information collected for entries within the CDF. It found that, overall, the CDF, under the new framework, included 12 drugs for 17 different indications, most commonly non-small-cell lung cancer (n = 4), urothelial cancer (n = 3) and lymphocytic leukaemia (n = 2). In ten cases, inclusion in the CDF followed a company submission pursuing this, which indicates a clear reimbursement strategy option for treatments with immature clinical evidence, such as overall survival and/or a significant price premium to existing treatments.
The preferred or base-case ICERs were generally higher than £20,000 per QALY, the limit at which NICE is likely to accept a technology for routine use [30] . The companys' base-case ICERs were generally lower than the committee's and the ERG's were higher than the committee's and the company's; in some cases, this difference was substantial. For example, for nivolumab in treatment of non-squamous programmed death-ligand 1 (PD-L1)-positive NSCLC, the committee's preferred ICER was more than twice as high as the company's. In reality, this difference may be smaller if a PAS is agreed between the company and the Department of Health. Nevertheless, these differences in the results reflect the uncertainty around the clinical evidence and the methodological approaches between the companies and the reviewing groups (committee, ERG).
A large proportion of drugs included in the CDF were intended for end-of-life care. Usually, the company ICERs fell under the £50,000 per QALY threshold acceptable in the current approach as described by NICE [31] . It is interesting that, although the criterion for end-of-life care is "short life expectancy, normally less than 24 months" [31] , the majority of CDF entries had data collection agreements lasting longer than the suggested usual maximum of 2 years. This is likely happening because the end-of-life care criteria considers the patient life expectancy, whereas the MAA duration includes time for recruitment of a sufficient number of patients. For rare conditions, recruitment of patients may be a protracted process. Nevertheless, the requirement for more evidence on overall survival in almost all cases suggests that 2 years may be insufficient to gain mature evidence on this outcome.
With regards to the inclusion of rare diseases, we noted that the dataset included a number of rare cancers such as Merkel cell carcinoma, Waldenstrom's macroglobulinaemia and lymphocytic leukaemia [32] , which have limited treatment options. In such cases, there may be additional incentives to making these treatments available to patients or at least further investigating their efficacy and safety. Benefits may include providing early access to already limited treatment options in populations where patients do not have 2 years to wait for further data to become available.
The main methods of data collection, in accordance with the CDF strategy [13] , were NHS systems, including Blueteq and the SACT dataset (used in all cases). In most of the cases, inclusion to the CDF involved ongoing clinical trials. This suggests that the CDF could be considered as a route for cancer drugs to become available for use within the NHS at an earlier point in their development than in other disease areas.
Some concerns around the CDF may include the benefit and safety of treatment with drugs for which clinical trials have yet to be completed. After all, the outcomes for data collection were efficacy (overall survival, progression-free survival, tumour response) patient HRQoL and safety. Drugs entering the CDF are all licensed by the European Medicines Agency, suggesting sufficient regulatory control to ensure a balance between safety and efficacy. It may be inferred then that the main sources of uncertainty for NICE surround the ICER and generalisability of evidence to the UK. Collection of data such as treatment patterns supports this idea. The   Fig. 4 Preferred of base-case ICERs for the company, committee and ERG. a Summary of ICER levels from the three stakeholders: data were available for 15 indications for the company and committee and nine indications for the ERG. b Company-, committee-and ERGpreferred ICERs (£/QALY) for all CDF entries: Some of the ICERs were not available in the documents identified. DEX dexamethasone, EGFR epidermal growth factor receptor, ERG evidence review group, ICER incremental cost-effectiveness ratio, IXA ixazomib, LEN lenalidomide, LL lymphocytic leukaemia, NSCLC non-small-cell lung cancer, PD-L1 programmed death-ligand 1, QALY quality-adjusted life-year, TP53 tumour protein 53, WM Waldenstrom's macroglobulinaemia ◂ additional data collection is only undertaken when there is potential for the drug to fall within an acceptable threshold at a future appraisal once the uncertainty is addressed. In addition, to enter the CDF, the company needs to reduce the drug price to account for the uncertainty [13] . If the drug price remains high, there may be a risk the drug would not be entered in the CDF. An interesting argument has been presented for improvement to the CDF whereby the budget would produce more valuable health [11] . Each drug would be ranked based upon its effect on patient health and the expected value of information gained from the data collected during the MAA.
Discrepancies between the identified sources of uncertainty and data collected were frequently observed and may have been due to a number of factors. It is possible that the documents available to the public may have been incomplete and information on sources of uncertainty and data collection was not reported in full. In a large number of documents, it was stated that information had been redacted. Information may also have been reported in documents that are out of the public domain. It is also possible that information on these two aspects included different levels of detail, as it appeared that data collection was generally Red cases highlight where for the same 'theme' data has been collected to a greater and lesser extent than what was reported as the corresponding source of uncertainty, e.g. Nivolumab (squamous-cell head and neck carcinoma) had more data collected for overall survival than was reported as a source of uncertainty AND less data collected on utility values than was reported as a source of uncertainty (both falling under the 'outcomes' theme) reported more extensively than what was considered sources of uncertainty. The SMC's criteria for considering treatments as endof-life care are broader in scope than those used by NICE. End-of-life medicines are defined by the SMC as "used to treat a condition at a stage that usually leads to death within 3 years with currently available treatments" [33] , whereas NICE criteria for appraising end-of-life treatments include indications for patients with a short life expectancy, normally < 24 months and sufficient evidence to indicate that the treatment offers an extension to life, normally of at least an additional 3 months, compared with current NHS treatment [34] . When compared with decisions in NHS Scotland, in most of the cases the treatments were accepted for routine use. This may suggest that the differences in decision may be due to the differences in what is considered end-of-life care and expectations relating to prolonging patients' lives.
Since the CDF has operated under the current framework for a relatively short period of time, the number of cases included and therefore in our analysis is limited. Further, some relevant information, such as ICER values obtained under PAS prices for drugs, was not publicly available. Additionally, the documents available, such as MAA or FAD, may not reflect the entirety of issues resulting in uncertainty around the effectiveness and cost effectiveness of the treatment that were under discussion before a decision was made for inclusion to the CDF. These in turn prevent us from drawing concrete conclusions on the existing framework. Updating the review with new evidence is essential to understand the service and the impact of the CDF on the NHS.
Conclusion
To our knowledge, this analysis is the first attempt to characterise drugs included in the CDF under the new rules. It appears that often drugs on the CDF are being made available for patients with advanced disease for whom prior treatments have failed and who are considered to require life-extending treatments. The uncertainty in the evidence seems to largely revolve around overall survival and is likely reflected by large discrepancies between ICERs and methodological approaches preferred by the company and the committee and ERG. The planned duration of data collection was frequently longer than 2 years and often involved continuation of an ongoing trial. This suggests the CDF is enabling patients to receive treatments that may otherwise not have been available during this time.
